Last updated: February 14, 2026
What Is the Current Market Status for NDC 00054-2527?
The drug identified by NDC 00054-2527 is Xeljanz (tofacitinib) Tablets, 5 mg. Manufactured by Pfizer, it is approved for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other autoimmune conditions.
As of 2023, Xeljanz remains a leading oral Janus kinase (JAK) inhibitor, with a U.S. prescription volume exceeding 1 million units annually. Market penetration is significant, especially in autoimmune disease treatment settings, driven by its efficacy profile and oral administration route.
How Is the Market for Xeljanz Evolving?
The JAK inhibitor class expands, with competing agents such as AbbVie's Rinvoq (upadacitinib) and Eli Lilly's Olumiant (baricitinib). These alternatives influence Xeljanz's market share and pricing strategies. The introduction of biosimilars is limited in this class; biologics like Humira face biosimilar competition.
Market analysts project steady growth in autoimmune indications through 2025, with a compound annual growth rate (CAGR) around 3-5%. Factors affecting growth include:
- Increasing approval for ulcerative colitis in the U.S. and Europe.
- Switching from biologics to oral JAK inhibitors.
- Patent exclusivity, which lasts until 2026 in the U.S. for some formulations.
What Are Price Trends and Projections?
Current Pricing (2023)
- Retail price per 30-day supply (5 mg, quantity 60): approximately $3,100–$3,300.
- Average wholesale acquisition cost (AWAC): approximately $2,950.
- Insurance reimbursement typically reduces patient out-of-pocket costs below $50 for covered patients.
Factors Influencing Price Stability and Trends
- Patent protection maintains pricing power.
- Entry of biosimilars for biologic competitors influences price competition but does not directly affect Xeljanz.
- Negotiations and preferred drug lists limit price erosion, especially in managed care settings.
- Price increases have averaged about 3–5% annually over recent years, aligning with inflation and R&D recovery costs.
Future Pricing Outlook (Next 3–5 Years)
Analysts predict modest price increases, around 2–4% annually, primarily driven by inflationary pressures and value-based reimbursement models.
The patent expiry authorized in 2026 could enable generic or biosimilar entry, although the timing and impact depend on regulatory pathways and market acceptance. Generic versions of tofacitinib would likely be priced 40-60% lower than branded Xeljanz, potentially reducing the drug's market share and overall revenue.
How Will Market Dynamics Affect Revenue and Pricing?
| Factor |
Effect on Price |
Effect on Revenue |
| Patent expiration |
Pressure for price reduction |
Revenue decline unless volume increases significantly |
| Competitive agents |
Price competition, potential discounts |
Market share redistribution |
| New indications |
Increased demand |
Revenue growth if approved and adopted |
| Biosimilar entry |
Lower price point, increased competition |
Potential revenue reduction unless offset by increased volume |
Key Market Players and Competitive Outlook
| Player |
Market Share (2023) |
Competitive Products |
| Pfizer |
~50% |
Rinvoq, Stelara, Humira (biosimilar) |
| AbbVie |
~25% |
Rinvoq, Skyrizi |
| Eli Lilly |
~5% |
Olumiant |
Xeljanz dominates the oral JAK inhibitor market but faces increasing competition from newer agents and upcoming generics.
Price Projections Summary
| Year |
Estimated Price Range (per 30-day supply) |
Notes |
| 2023 |
$3,100–$3,300 |
Current pricing, stable due to patent protection |
| 2024 |
$3,150–$3,430 |
Slight increase, market remains stable |
| 2025 |
$3,200–$3,560 |
Approaching patent expiration, price stabilization anticipated |
| 2026 |
$2,000–$2,300 (biosimilar entry expected) |
Potential generic/biosimilar impact |
Key Takeaways
- Xeljanz (tofacitinib) remains a high-value, branded oral immunomodulator with steady growth in autoimmune indications.
- Pricing is currently stable, with a slight upward trend driven by inflation and value-based pricing.
- Patent expiry in 2026 could significantly alter market share and pricing, with biosimilar options reducing costs.
- Competitive dynamics from biologic biosimilars and oral alternatives will influence future revenue streams.
- Market expansion into new indications and off-label uses may sustain revenue but are not guaranteed adjustments to price.
FAQs
1. When will generic or biosimilar versions of Xeljanz become available?
Patent expiry in the U.S. is scheduled for 2026, after which biosimilar versions could enter the market, pending regulatory approval and market acceptance.
2. How does Xeljanz pricing compare to its competitors?
Xeljanz's retail price is approximately $3,100–$3,300 per month. Rinvoq, a direct competitor, sells at similar prices, while biosimilars for biologic competitors like Humira are priced 40–60% lower.
3. What factors are most likely to influence Xeljanz's future market share?
Patent expiration, competition from new JAK inhibitors, biosimilar entry, and approval for additional indications are key factors.
4. How much revenue does Xeljanz generate annually?
Pfizer's 2022 reports indicate approximately $2 billion in global annual sales; the U.S. accounts for a significant portion of this revenue.
5. Are there pricing strategies to mitigate patent expiration impact?
Yes, Pfizer may employ pricing discounts, increased marketing efforts, and expanded indications to sustain revenue.
References
- Pfizer. (2023). Xeljanz (tofacitinib) prescribing information.
- IQVIA. (2023). Drug Trends: Rheumatoid arthritis market.
- Evaluated Pricing Data, Red Book. (2023).
- U.S. FDA. (2022). Patent and exclusivity data for Xeljanz.
- MarketWatch. (2023). Biopharma market projections and competition analysis.
